Lukas Biomedical

Lukas Biomedical EBIT Margin

The EBIT Margin (Operating Margin) of Lukas Biomedical (6814.TWO) as of Oct 27, 2026 is -45.21 %. In the previous year, EBIT Margin (Operating Margin) was -48.54 % — a change of -6.86% (higher).

EBIT Margin

-45.21 %

YoY

-6.86%

Last updated:

EBIT Margin (Operating Margin) of Lukas Biomedical is 2025 -45.21 % . EBIT Margin (Operating Margin) of Lukas Biomedical was 2024 -48.54 % . It decreases by -6.86% higher compared to the previous year.

For Lukas Biomedical, the operating (EBIT) margin of -45.2% is down versus -27.3% a few years ago.

The Lukas Biomedical EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-3.82 TWD
Jan 1, 2019
-4.60 TWD
Jan 1, 2020
-3.57 TWD
Jan 1, 2021
-27.32 TWD
Jan 1, 2022
-26.23 TWD
Jan 1, 2023
-18.79 TWD
Jan 1, 2024
-48.54 TWD
Jan 1, 2025
-45.21 TWD
The Lukas Biomedical EBIT Margin history
YEAREBIT MarginYoY
-45.21 %-6.86%
-48.54 %+158.32%
-18.79 %-28.36%
-26.23 %-4.00%
-27.32 %+664.75%
-3.57 %-22.30%
-4.60 %+20.50%
-3.82 %+97.32%
-1.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lukas Biomedical Stock analysis

What does Lukas Biomedical do? Lukas Biomedical, Inc. generates revenue through the lease and sale of medical equipment, as well as the research, design, development, and manufacture of immune cell products. The company offers beauty cosmetics, skin care products, and daily necessities such as dental floss, chewing gum, chewing spray, and dry hair products. Its makeup series includes eye shadow gel, eye color palette, lip gloss, lipstick, and lip wax. The firm provides services like brand authorization, management consulting, property leasing, and medical equipment leasing under an experience charging model for care institutions and medical management. The company’s products target consumers in the beauty and healthcare sectors, with medical equipment leased to care institutions and medical management entities. Immune cell products are developed for medical applications, while beauty and daily necessity products cater to personal care markets. The firm’s service model combines brand authorization with property and equipment leasing to support operational experience in healthcare facilities. Lukas Biomedical’s revenue streams include direct sales of medical equipment, lease agreements for medical devices, and the sale of immune cell products, beauty cosmetics, and daily necessities. Care institutions and medical management companies are key clients for leasing services, while beauty product lines serve individual consumers and retail channels. The experience charging model integrates brand authorization and management consulting to enhance service offerings for healthcare providers. Lukas Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lukas Biomedical stock

EBIT Margin (Operating Margin) of Lukas Biomedical is -45.21 % in 2025.

EBIT Margin (Operating Margin) of Lukas Biomedical changed from -48.54 % to -45.21 %, representing a -6.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Lukas Biomedical since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Lukas Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Lukas Biomedical

All Key Metrics — Lukas Biomedical